Puma Biotechnology (PBYI)
(Delayed Data from NSDQ)
$2.95 USD
+0.10 (3.51%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $2.94 -0.01 (-0.34%) 7:58 PM ET
4-Sell of 5 4
A Value C Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.95 USD
+0.10 (3.51%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $2.94 -0.01 (-0.34%) 7:58 PM ET
4-Sell of 5 4
A Value C Growth B Momentum A VGM
Zacks News
Bristol Myers' (BMY) Krazati sNDA for CRC Gets Priority Review
by Zacks Equity Research
Bristol Myers (BMY) announces FDA's acceptance of the sNDA seeking approval for the Krazati/Erbitux combo therapy to treat CRC patients. A final decision is expected on Jun 21, 2024.
Bayer (BAYRY) Intends to Slash Dividends Amid Challenges
by Zacks Equity Research
Bayer (BAYRY) announced plans to cut dividends to pay out only the legally required minimum for three years in the wake of high debt and increasing legal costs.
Pfizer's (PFE) Ulcerative Colitis Pill Velsipity Gets EU Nod
by Zacks Equity Research
The approval for Pfizer's (PFE) Velsipity (etrasimod) is based on data from two pivotal phase III studies, ELEVATE UC 52 and ELEVATE 12.
Roche's (RHHBY) Xolair Gets Approval for Food Allergies
by Zacks Equity Research
Roche (RHHBY) obtains FDA approval for Xolair for the treatment of children and adults with one or more food allergies.
Iovance (IOVA) Stock Rises on FDA Nod for Melanoma Drug Amtagvi
by Zacks Equity Research
The FDA grants accelerated approval to Iovance's (IOVA) Amtagvi (lifileucel) for treating advanced melanoma after anti-PD-1 and targeted therapy. Stock rises.
TScan Therapeutics, Inc. (TCRX) Stock Jumps 18.1%: Will It Continue to Soar?
by Zacks Equity Research
TScan Therapeutics, Inc. (TCRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Corcept (CORT) Q4 Earnings Beat Estimates, Korlym Sales Grow
by Zacks Equity Research
Corcept (CORT) beats on both earnings and sales in the fourth quarter. The company also reiterates its previously provided guidance for 2024.
Agios (AGIO) Q4 Earnings & Revenues Fall Short of Estimates
by Zacks Equity Research
Agios' (AGIO) earnings and revenues miss estimates in the fourth quarter of 2023. Revenues from its sole marketed drug, Pyrukynd, rise year over year.
Ultragenyx (RARE) Q4 Loss Narrower Than Expected, Revenues Beat
by Zacks Equity Research
Ultragenyx (RARE) reports better-than-expected fourth-quarter 2023 results, beating both earnings and revenue estimates, driven by strong sales trends of Crysvita and Dojolvi.
Blueprint (BPMC) Q4 Earnings Beat, Stock Up as Ayvakit Shines
by Zacks Equity Research
Blueprint (BPMC) climbs 14% on better-than-expected fourth-quarter 2023 results, driven by increased Ayvakit sales following the drug's label expansion for the ISM indication.
Sage Therapeutics (SAGE) Q4 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Sage Therapeutics' (SAGE) earnings and revenues surpass estimates in the fourth quarter of 2023. Focus on newly launched PPD drug, Zurzuvae. Stock rise.
Alkermes' (ALKS) Q4 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Alkermes' (ALKS) earnings and revenues outpace estimates in the fourth quarter of 2023. Strong growth in proprietary products drives year-over-year revenues.
Zacks Industry Outlook Highlights Sarepta, Exelixis, Immunocore, Editas and Puma Biotechnology
by Zacks Equity Research
Sarepta, Exelixis, Immunocore, Editas and Puma Biotechnology have been highlighted in this Industry Outlook article.
Zoetis' (ZTS) Q4 Earnings Miss Expectations, Sales Beat
by Zacks Equity Research
Zoetis (ZTS) reports mixed fourth-quarter results, wherein earnings miss estimates while revenues beat the same.
Biogen (BIIB) Q4 Earnings & Sales Miss Estimates, Stock Falls
by Zacks Equity Research
Biogen (BIIB) misses fourth-quarter estimates for earnings and sales. Sales of Tecfidera, Tysabri & Spinraza decline.
5 Biotech Stocks to Consider for Your Portfolio in 2024
by Ekta Bagri
New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position SRPT, EXEL, IMCR, EDIT and PBYI well amid volatility.
Immunovant (IMVT) Up 3% as Q3 Earnings Top, Pipeline in Focus
by Zacks Equity Research
Immunovant (IMVT) gains 3% on encouraging fiscal third-quarter 2024 results. Pipeline development is on track, with several data readouts scheduled from both batoclimab and IMVT-1402 programs.
Strength Seen in Puma Biotech (PBYI): Can Its 10.0% Jump Turn into More Strength?
by Zacks Equity Research
Puma Biotech (PBYI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Corvus' (CRVS) Lymphoma Drug Gets Orphan Status, Stock Up
by Zacks Equity Research
Corvus' (CRVS) lead candidate, soquelitinib, gets orphan drug designation in the United States. The company???s shares rise 10.75% on the news.
Humacyte (HUMA) Up on HAV BLA Priority Tag for Vascular Trauma
by Zacks Equity Research
Humacyte (HUMA) gains 16% as the FDA accepts its BLA for the HAV bioengineered tissue to treat vascular trauma under Priority Review. A final decision is expected in August 2024.
PBYI vs. AMGN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PBYI vs. AMGN: Which Stock Is the Better Value Option?
Foghorn (FHTX) Jumps 55% as Lilly Takes Up FHD-909 Development
by Zacks Equity Research
Foghorn (FHTX) gains 55% as its strategic collaboration partner, Lilly, selects the pre-clinical candidate, FHD-909, for clinical development.
Bristol Myers' (BMY) Opdivo Label Expansion Filings Get Accepted
by Zacks Equity Research
Bristol Myers (BMY) announces the acceptance of its regulatory filings for the perioperative Opdivo regimen to treat a lung cancer indication in the United States and EU.
JAZZ Boosts Oncology Pipeline With KRAS Inhibitor Program
by Zacks Equity Research
JAZZ inks a deal to acquire global rights to Redx Pharma's KRAS inhibitor program to strengthen its early-stage oncology pipeline.
REGENXBIO's (RGNX) Hunter Syndrome Study Meets Goal, Stock Up
by Zacks Equity Research
REGENXBIO (RGNX) gains 12% on positive top-line results from the phase I/II/III study of its investigational one-time gene therapy candidate, RGX-121, to treat pediatric patients with Hunter syndrome.